{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:45:00Z","timestamp":1770486300073,"version":"3.49.0"},"reference-count":20,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1507\/endocrj.ej15-0097","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T22:01:52Z","timestamp":1431468112000},"page":"593-603","source":"Crossref","is-referenced-by-count":25,"title":["Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise"],"prefix":"10.1507","volume":"62","author":[{"given":"Yutaka","family":"Seino","sequence":"first","affiliation":[{"name":"Kansai Electric Power Hospital, Osaka 553-0003, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[{"name":"Kawasaki Medical School, Department of Internal Medicine, Kurashiki 701-0192, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine, Department of Diabetes, Endocrinology and Nutrition, Kyoto 606-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Haneda","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, The Jikei University Graduate School of Medical Research, Tokyo 105-8461, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Fukatsu","sequence":"additional","affiliation":[{"name":"Yachiyo Hospital, Anjo 446-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michito","family":"Ubukata","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd., Tokyo 170-8633, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd., Tokyo 170-8633, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshishige","family":"Samukawa","sequence":"additional","affiliation":[{"name":"Taisho Pharmaceutical Co., Ltd., Tokyo 170-8633, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","unstructured":"1. International Diabetes Federation. IDF Diabetes Atlas. 6th edn. Available from: http:\/\/www.idf.org\/diabetesatlas\/ [Last accessed 2nd February 2015]"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Grundy SM (2008) Metabolic syndrome pandemic. <i>Arterioscler Thromb Vasc Biol<\/i> 28: 629-636.","DOI":"10.1161\/ATVBAHA.107.151092"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care<\/i> 35: 1364-1379.","DOI":"10.2337\/dc12-0413"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ahren B (2012) DPP-4 inhibition and islet function. <i>J Diabetes Investig<\/i> 3: 3-10.","DOI":"10.1111\/j.2040-1124.2011.00184.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Seino Y, Yabe D (2013) Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. <i>J Diabetes Investig<\/i> 4: 108-130.","DOI":"10.1111\/jdi.12065"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, et al. (2014) Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. <i>Curr Med Res Opin <\/i>30: 1231-1244.","DOI":"10.1185\/03007995.2014.909390"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, et al. (2014) Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. <i>Curr Med Res Opin <\/i>30: 1245-1255.","DOI":"10.1185\/03007995.2014.912983"},{"key":"8","unstructured":"8. Guideline for clinical evaluation of oral hypoglycemic agents. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2010. Available from: http:\/\/www.pmda.go.jp\/kijunsakusei\/guideline.html [Last accessed 2nd February 2015]"},{"key":"9","unstructured":"9. ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1994. Available from: http:\/\/www.ich.org\/products\/guidelines\/efficacy\/article\/efficacy-guidelines.html [Last accessed 2nd February 2015]"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kashiwagi A, Kasuga M, Araki E, Ota Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. <i>Diabetol Int<\/i> 3: 8-10.","DOI":"10.1007\/s13340-012-0069-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, et al. (2014) Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, Phase II study. <i>Curr Med Res Opin<\/i> 30: 1219-1230","DOI":"10.1185\/03007995.2014.901943"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Odawara M, Kadowaki T, Tajima N, Nishii M,Taniguchi T, et al. (2011) Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. <i>Diabetol Int<\/i> 2: 94-105.","DOI":"10.1007\/s13340-011-0029-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Abdul-Ghani MA, DeFronzo RA, Norton L (2013) Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. <i>Diabetes <\/i>62: 3324-3328.","DOI":"10.2337\/db13-0604"},{"key":"14","unstructured":"14. Canagliflozin (Invokana<sup>&reg<\/sup>): prescribing information. Available from: http:\/\/www.invokanahcp.com\/prescribing-information.pdf\/"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, et al. (2013) Urinary tract infections in patients with diabetes treated with dapagliflozin. <i>J Diabetes Complications<\/i> 27: 473-478.","DOI":"10.1016\/j.jdiacomp.2013.05.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, et al. (2013) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. <i>J Diabetes Complications<\/i> 27: 479-484.","DOI":"10.1016\/j.jdiacomp.2013.04.012"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. <i>N Engl J Med<\/i> 355: 2427-2443.","DOI":"10.1056\/NEJMoa066224"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M (2010) Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight. <i>Diabetes Obes Metab<\/i> 12: 510-516.","DOI":"10.1111\/j.1463-1326.2010.01216.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. <i>Kidney Int <\/i>85: 962-971.","DOI":"10.1038\/ki.2013.356"},{"key":"20","unstructured":"20. Haneda M, Seino Y, Sasaki T, Fukatsu A, Samukawa Y, et al. (2012) Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control in Japanese type 2 diabetic subjects with renal impairment. 48th European Association for the Study of Diabetes (EASD) Annual Meeting, October 1-5, 2012. Berlin, Germany. (Abstract)"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/7\/62_EJ15-0097\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T11:28:29Z","timestamp":1498217309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/7\/62_EJ15-0097\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej15-0097","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}